(A, B) Western blot of DHX29-sgRNA-Cas9 LentiCRISPR transduced 293T cells (A) or MEFs (B) after puromycin selection and SURVEYOR assays. (C, D) SURVEYOR assay of DHX29-sgRNA-Cas9 LentiCRISPR mixture transduced human PBMC (C) or murine cell (BMDC, pMAC) (D) after puromycin selection. (E-G) Immunoblot analysis of p-TBK1 in control sgRNA- or DHX29 sgRNA-transduced PBMC (E), BMDC (F), or peritoneal macrophages (pMAC) (G), left untreated or stimulated by LMW Poly(I:C). VSV, Poly(dA:dT), EMCV or HMW Poly(I:C). (H) Morphology of Control-Cas9 or DHX29-sgRNA-Cas9 LentiCRISPR transduced pMAC at Day 9 post transduction. Scale bar = 10μm. Related to Fig 3 in the main text.